Migraine Disorders Clinical Trial
Official title:
A Single Dose, Placebo-Controlled, Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of ALD403, a Humanized Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody Administered by Intravenous Infusion and Subcutaneous Injection
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALD403, a monoclonal antibody, administered by intravenous infusion and subcutaneous injection.
Status | Completed |
Enrollment | 104 |
Est. completion date | April 2013 |
Est. primary completion date | December 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria Part A: - Healthy males and females between the ages of 18 and 65 (inclusive). - Normal renal function as calculated by the Cockcroft- Gault equation at screening. - Body Mass Index (BMI) between 18.0 and 30.0 kg/m2, and a total body weight of 50 to 100kg inclusive. - No clinically significant disease or abnormal laboratory values as determined by medical history, physical examination, electrocardiogram, and laboratory evaluations Exclusion Criteria Part A: - History of febrile illness within 5 days prior to the first dose - Any clinically significant laboratory findings - Any clinically significant physical exam abnormalities - Hospitalization for any reason within 30 days of the screening visit. - History of or positive human immunodeficiency virus (HIV) screen result - History of positive Hepatitis B surface antigen (HBsAg), and/or positive Hepatitis C antibody (HCV) at screening. - History of malignancy within five years prior to screening. - History of leukemia, myeloproliferative disorder or lymphoproliferative disorder - History of rubber, latex allergy or allergy to medical adhesives - Positive urine, drug or alcohol screen result - Current smokers - Previous treatment or clinical trial with a monoclonal antibody. - Participation in any clinical research study evaluating another investigational drug or therapy within 30 days or at least 5 half-lives Inclusion Criteria Part B: - Healthy females between the ages of 18 and 65 (inclusive). - Male and female migraine patients with clinically diagnosed migraine not attributed to another cause with or without aura based on International Headache Society criteria. - Migraine patients must have a history of migraine with or without aura for more than 1 year with 1-8 moderate or severe migraine attacks per month in the 2 months prior to starting in the study. - Normal renal function as defined by Cockcroft- Gault equation at screening. - Body Mass Index (BMI) between 18.0 and 30.0 kg/m2, and a total body weight of 50 to 100kg inclusive. - No clinically significant disease or abnormal laboratory values as determined by medical history, physical examination, electrocardiogram, and laboratory evaluations conducted at the screening visit or at the time of admission Exclusion Criteria Part B: - For migraine patients: patient is not able to refrain from use of their usual triptan therapy (if applicable) from 48 hours (Day -2) prior to dosing on Day 1 until the morning of discharge (Day 3). - Migraine patients who experience migraine with prolonged aura, familiar hemiplegic migraine, migrainous infarction or basilar migraine - For migraine patients: patient has more than 8 headache-days per month or has taken medication for acute headache on more than 8 days a month in the past 3 months - For migraine patients: patient was greater than 50 years old at the age of migraine onset - History of febrile illness within 5 days prior to the first dose - Any clinically significant laboratory findings - Any clinically significant physical exam abnormalities - Previous treatment or clinical trial with a monoclonal antibody. - Hospitalization for any reason within 30 days of the screening visit. - History of or positive human immunodeficiency virus (HIV) screen result - History of positive Hepatitis B surface antigen (HBsAg), and/or positive Hepatitis C antibody (HCV - History of malignancy within five years prior to screening. - History of leukemia, myeloproliferative disorder or lymphoproliferative disorder - Positive urine drug or alcohol screen result - Current smokers. - Known contraindication to sumatriptan - Participation in any clinical research study evaluating another investigational drug or therapy within 30 days or at least 5 half-lives |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Australia | Centre for Clinical Studies, Nucleus Network | Melbourne | Victoria |
Lead Sponsor | Collaborator |
---|---|
Alder Biopharmaceuticals, Inc. |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and tolerability of ALD403: laboratory variables, ECG and adverse events | Physical Examination Vital signs 12-lead ECG (electrocardiogram) Clinical laboratory tests (hematology, chemistry) Number of participants with Adverse Events |
12 weeks | Yes |
Secondary | Evaluation of Pharmacokinetics of ALD403 | Cmax - maximum plasma concentration Tmax - Time to achieve maximum plasma concentration AUC - Area under the plasma concentration-time curve T1/2 - Elimination half-life Vz - Volume of distribution CL - Clearance Bioavailability |
12 weeks | No |
Secondary | Evaluation of pharmacodynamics of ALD403 | Blood perfusion rates Plasma levels of unbound ALD403 Immunogenicity |
12 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01432379 -
BOTOX® Prophylaxis in Patients With Chronic Migraine
|
||
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Recruiting |
NCT05048914 -
Migraine Abortive Treatment
|
||
Completed |
NCT03662295 -
Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention
|
||
Completed |
NCT02766517 -
Biomarker Study in Participants With Migraine
|
Early Phase 1 | |
Completed |
NCT00963937 -
Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents
|
Phase 3 | |
Not yet recruiting |
NCT03632928 -
Day to Day Variation of Pressure Pain Threshold and Muscle Hardness
|
||
Completed |
NCT02559895 -
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
|
Phase 3 | |
Completed |
NCT01435941 -
Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine
|
N/A | |
Completed |
NCT00743015 -
Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks
|
Phase 1 | |
Completed |
NCT01376141 -
Drug Use Investigation for IMIGRAN Tablet
|
N/A | |
Completed |
NCT02183688 -
Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients
|
Phase 3 | |
Completed |
NCT06061588 -
"Potential Effects of Virtual Reality Technology on the Treatment of Migraine-Type Headaches"
|
N/A | |
Completed |
NCT03588364 -
The Role of Osteopathic Manipulation in the the Management of Post-traumatic Migraine
|
N/A | |
Completed |
NCT04091321 -
Association Between Chronic Headache and Back Pain With Childbirth
|
||
Completed |
NCT00385008 -
TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine
|
Phase 3 | |
Active, not recruiting |
NCT05888298 -
Proximal and Distal Approach GON RFT in Migraine
|
N/A | |
Completed |
NCT03435185 -
Greater Occipital and Supraorbital Nerve Blockade in Migraine Patients
|
N/A | |
Recruiting |
NCT06459635 -
Migraine Attack Pain Phase Prediction Study
|
||
Completed |
NCT02565186 -
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
|
Phase 3 |